Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.77 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645653 | 0.87 | VCAM1 (1.00) | VCAM1GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4167481 | 0.82 | VCAM1 (0.59) | VCAM1GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9899802 | 0.79 | VCAM1 (0.77) | VCAM1GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL15413658 | 0.79 | VCAM1 (0.77) | VCAM1GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL15408517 | 0.79 | VCAM1 (0.77) | VCAM1GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2085253 | 0.76 | VCAM1 (0.66) | VCAM1GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2810707 | 0.76 | GPR35 (0.57) | VCAM1GPR35ALDH1A1CYP3A4HPGD | |
| SCHEMBL25258938 | 0.76 | VCAM1 (0.70) | VCAM1GPR35GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31326843 | 0.75 | VCAM1 (0.64) | VCAM1GPR35ALDH1A1HPGDALOX15 | |
| SCHEMBL31432469 | 0.75 | VCAM1 (0.59) | VCAM1GPR35MERTKALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | LUPIN LIMITED (IN) | 2025-11-25 | — | — | US | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| CN-114174303-B | Macrocyclic compounds as STING agonists and methods and uses thereof | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | LUPIN LIMITED (IN) | 2022-09-15 | — | — | US | disclosed |
| EP-4004002-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | Lupin Limited (IN) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174303-A | Macrocyclic compounds as STING agonists, methods and uses thereof | 印度鲁宾有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021014365-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021014365-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| CN-104470925-B | Imidazo-triazine formonitrile HCN as kinase inhibitor | 百时美施贵宝公司 | 2017-12-05 | — | — | CN | disclosed |
| US-8940736-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| WO-2014011974-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-16 | — | — | US | disclosed |
| CN-1136192-C | Aryl and heteroaryl sulfonamide derivatives, their preparation and their use as endothelin antagonists | - | 2004-01-28 | — | — | CN | disclosed |
| EP-0799206-B1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6133442-A | FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5962682-A | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN-LA ROCHE INC. (US) | 1999-10-05 | — | — | US | disclosed |
| CN-1170405-A | Aryl and heteroaryl sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN LA ROCHE (CH) | 1998-01-14 | — | — | CN | disclosed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | STING1, CGAS, MAVS | VCAM1 3553/4885GPR35 60/4885GRIN2D 4214/4885 |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | VCAM1 4191/4885GPR35 3725/4885GRIN2D 3686/4885 |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | STING1, CGAS, MAVS | VCAM1 3553/4885GPR35 60/4885GRIN2D 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.